Product Images Aripiprazole

This appears to be a diagram or figure depicting the effects of other drugs on the pharmacokinetics of aripiprazole. The figure shows the fold change and 90% confidence interval of various parameters (such as AUC and Cmax) for aripiprazole in the presence of different drugs that inhibit or induce certain enzymes (such as CYP3A4 and CYP2D6). Additionally, the figure includes the effects of gastric acid blockers and two other drugs (valproate and lorazepam). The specific numeric values and units are not clear from the text, so more context may be needed to fully understand the information presented in the figure.*

This is a description of the effects of different drugs on the pharmacokinetics of aripiprazole. The drugs studied include ketoconazole, quinidine, carbamazepine, famotidine, valproate, and lorazepam. The fold changes and 90% confidence intervals of dehydro-aripiprazole PK are presented in Figure 2.*

The text suggests a figure (Figure 3) showing the effects of aripiprazole on the pharmacokinetics of other drugs. The figure likely demonstrates the fold change and 90% confidence interval for the changes in parameters such as AUC and Cmax for drugs including extropmethorphan, Swartarin, Revartarin, omeprazole, lamotrigine, valproate, lorazepam, yontane, and O-desmethyivenlafaxine. The changes appear to range from 5% to 30%.*

This appears to be a table showing the impact of PK AdpprzcleFad on special populations. The table compares changes in various factors between different groups such as females vs males, different age groups, and different levels of hepatic and renal impairment. Unfortunately, without additional context or a clearer image, it is difficult to provide more information.*

This is a figure showing the effects of various intrinsic factors on dehydro-aripiprazole pharmacokinetics. The factors evaluated include gender, age, hepatic impairment, and renal impairment. The figure depicts the change and 90% confidence interval (CI) in PK Dehydro-Aripiprazole between each factor and the reference. The x-axis represents the relative change on a scale of 0 to 30.*

This is a Kaplan-Meier plot of the cumulative proportion of patients with relapse in Schizophrenia Study 5. The plot displays the proportion of patients who experienced a relapse over time for those treated with aripiprazole versus those who received a placebo. The x-axis shows the number of subjects at risk, and the y-axis indicates the proportion with relapse. Days from randomization is also shown on the plot.*

This is a medicine container of Aripiprazole 2mg with lot number #0000, containing 30 green coloured, modified rectangular shaped, uncoated tablets debossed with ‘61'on one side and ‘H' on other side. The medication guide is provided separately and should be dispensed to each patient along with the container. The medicine should be stored at a temperature between 20°C-25°C and has an expiry date of 00/00/00. This product is manufactured by Aurobindo Pharma Limited and distributed by ProficientRx located in Thousand Oaks, CA. This product is for prescription use only and should be kept out of the reach of children.*